Valopicitabine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Valopicitabine}} | ||
}} | |||
== Valopicitabine == | |||
[[File:Valopicitabine_structure.png|thumb|right|Chemical structure of Valopicitabine]] | |||
'''Valopicitabine''' is an investigational antiviral drug that was developed for the treatment of [[hepatitis C virus]] (HCV) infection. It is a prodrug of [[NM283]], which is a nucleoside analog that inhibits the replication of HCV by targeting the viral [[RNA polymerase]]. | |||
Valopicitabine is | |||
== | == Mechanism of Action == | ||
Valopicitabine | Valopicitabine is converted in the body to its active form, NM283, which is a nucleoside analog. NM283 mimics the natural substrates of the HCV RNA-dependent RNA polymerase, thereby inhibiting the replication of the viral genome. This inhibition prevents the virus from multiplying and spreading within the host. | ||
== | == Clinical Development == | ||
Valopicitabine was studied in several clinical trials to assess its efficacy and safety in patients with chronic hepatitis C. The drug showed promise in early-phase trials, demonstrating a reduction in viral load in patients. However, further development was halted due to concerns about its side effect profile and the emergence of more effective treatments for HCV. | |||
==Related | == Side Effects == | ||
During clinical trials, valopicitabine was associated with several side effects, including gastrointestinal disturbances such as nausea and diarrhea. Some patients also experienced elevated liver enzymes, which indicated potential liver toxicity. These adverse effects contributed to the decision to discontinue its development. | |||
== Related Pages == | |||
* [[Hepatitis C]] | * [[Hepatitis C]] | ||
* [[Antiviral drug]] | * [[Antiviral drug]] | ||
* [[RNA polymerase]] | |||
* [[Nucleoside analog]] | * [[Nucleoside analog]] | ||
[[Category:Antiviral drugs]] | [[Category:Antiviral drugs]] | ||
[[Category: | [[Category:Hepatitis C treatments]] | ||
Latest revision as of 05:33, 16 February 2025
Valopicitabine[edit]
Valopicitabine is an investigational antiviral drug that was developed for the treatment of hepatitis C virus (HCV) infection. It is a prodrug of NM283, which is a nucleoside analog that inhibits the replication of HCV by targeting the viral RNA polymerase.
Mechanism of Action[edit]
Valopicitabine is converted in the body to its active form, NM283, which is a nucleoside analog. NM283 mimics the natural substrates of the HCV RNA-dependent RNA polymerase, thereby inhibiting the replication of the viral genome. This inhibition prevents the virus from multiplying and spreading within the host.
Clinical Development[edit]
Valopicitabine was studied in several clinical trials to assess its efficacy and safety in patients with chronic hepatitis C. The drug showed promise in early-phase trials, demonstrating a reduction in viral load in patients. However, further development was halted due to concerns about its side effect profile and the emergence of more effective treatments for HCV.
Side Effects[edit]
During clinical trials, valopicitabine was associated with several side effects, including gastrointestinal disturbances such as nausea and diarrhea. Some patients also experienced elevated liver enzymes, which indicated potential liver toxicity. These adverse effects contributed to the decision to discontinue its development.
